DOCSLIB.ORG

ASN Kidney Week 2019 Disclosures 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ASN Kidney Week 2019 Disclosures 1 10/22/2019 ASN Kidney Week 2019 Disclosures 1 Nothing to Full Name Organization Current Employer Consultancy Ownership Interest Research Funding Honoraria Patents and Inventions Scientific Advisor or Membership Speakers Bureau Other Interests/Relationships Disclose Soraya Abad HOSPITAL GREGORIO MARAÑON Hospital General Universitario Gregorio Marañon Stephen Abbott, PhD university of virginia Mario Abbud-Filho, MD Medical School - FAMERP Medical School - FAMERP Emaad M. Abdel-Rahman, MD, PhD, FASN University of Virginia University of Virginia Reza Abdi, MD Transplant Research Center BWH Sohail Abdul Salim, MD, MBBS, FASN University of Mississippi Medical University of Mississippi Medical Editorial Board Of Journals: Renal Centre Centre; Central Nephrology Failure, Journal Of Medical Case Reports, Intec Publishers. Chikara Abe, PhD University of Virginia Gifu University Graduate School of Medicine Masanori Abe, MD, PhD Nihon University School of Medicine Nihon University School of Medicine Kyowa Hakko Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Tanabe Mitsubishi Pharmaceutical Co., Ltd. Takaaki Abe, MD, PhD Tohoku University Hospital Tohoku University Hospital Boehringer Ingelheim, Daiichi- Boehringer Ingelheim, Daiichi- Sankyo, MSD, Astellas Pharma, Sankyo, DaiNippon-Sumitomo Takeda Pharmaceutica. Kreha. ALA Pharmaceutical, Ono Pharmaceutical, Promo Pharm., Novartis Astra-Zeneka Pharmaceutical; Pharmaceutical K.K., Japan Kidney Astellas Pharmaceutical Fundation, DaiNippon-Sumitomo Pharmaceutical Tanabe Mitsubisihi Khodor Abou Daya, MD Starzl Transplantation Institute Starzl Institute of Transplantation Karam S. Aboudehen, PhD University of Minnesota University of Minnesota Kenneth D. Abreo, MD Louisiana State University Health Akebia Editorial Board: Journal of Vascular Sciences Center Access, Seminars in Dialysis (ASDIN), Open Journal of Urology and Nephrology, Advances in Nephrology; Executive Committee, American Society of Diagnostic and Interventional Nephrology (ASDIN) Zita C. Abreu, RN UHN UHN Ala Abudayyeh, MD University of Texas MD Anderson University of Texas MD Anderson Cancer Center Cancer Center Jennifer Aceves-Ripoll Fundación Investigación Biomédica Fundación Investigación Biomédica I+12 Hospital 12 de Octubre Adebola O. Adeleye, DNP CMS CMS Deborah B. Adey, MD University of California, San Francisco University of California, San Francisco Hansa Biopharma American Society of Transplantation (AST), Board of Managers for the Transplant Nephrology Accreditation Program; AST- board - councilor at large; American Board of Internal Medicine; Hansa Biopharma Adebowale A. Adeyemo, MD National Institutes of Health National Institutes of Health Sharon G. Adler, MD, FASN Harbor-UCLA Medical Center Retrophin; Bristol Meyers Squibb; Retrophin; Bayer; Bristol Meyers Bayer; Retrophin; Bristol Meyers KDIGO Bayer Pharmaceuticals; AstraZeneca; Squibb; ChemoCentryx; Omeros; Squibb; Bayer Pharmaceuticals; ChemoCentryx; Omeros; Zyversa Zyversa Therapeutics; Calliditas Zyversa; AstraZeneca Dwomoa Adu, MD University of Ghana University of Ghana Editorial Board Member, African Board of Trustees, Transplant Links Journal of Nepnrology Committee. UK Anamika Adwaney, MBBS Hammersmith Hospital Hammersmith Hospital; Imperial College Healthcare NHS Trust Farsad Afshinnia, MD, MS, FASN University of Michigan University of Michigan NIDDK K08-DK106523 Maryam Afzal, PhD University of Bristol University of Bristol John W. MacD. Agar, MBBS University Hospital Geelong University Hospital Geelong Quanta Dialysis Technologies - Quanta Dialysis Technologies - Quanta Dialysis Technologies - Advisor: Medical Education Institute Medical Advisory Board Medical Advisory Board Medical Advisory Board (MEI); Advisor: Home Dialysis Central Website (MEI) Anupam Agarwal, MD, FASN University of Alabama at Birmingham University of Alabama at Birmingham Dynamed - review content related to Goldilocks Therapeutics, Inc. Genzyme/Sanofi Fabry Fellowship Univ Southern California, Vanderbilt, Editorial Board of AJP Renal, Kidney My wife, Lisa Curtis, will be President- AKI and review updated materials Award Emory, Akebia therapeutics Int and Lab Investigation.; Advisory elect for Women in Nephrology (2018- prepared by Dynamed editorial team board of Goldilocks Therapeutics, a 2019). for AKI topics.; Akebia Therapeutics - NY based company investigating Expert Panel to review new delivery of drugs in the kidney using therapeutics based on the HIF nanotechnology for acute and chronic pathway for AKI. I serve as a kidney disease. External evaluation consultant for Reata Pharmaceuticals. panel for the Kidney Precision Medicine Program (KPMP). Advisory Arnav Agarwal, MD University of Toronto University of Toronto f Rajiv Agarwal, MD, MS, FASN VA Medical Center, Indiana Abbvie, Akebia, Amgen, Abbvie, Akebia, Amgen, KDIGO, Hypertension, NDT, AJN, University, IU Heath Physicians AstraZeneca, Bayer, Birdrock Bio, AstraZeneca, Bayer, Birdrock Bio, JASH, Seminars in Dialysis, Akebia,, Boehringer Ingelheim, Celgene, Boehringer Ingelheim, Celgene, AstraZeneca, Bayer, Boehringer Daiichi Sankyo, Eli Lilly, Daiichi Sankyo, Eli Lilly, Ingelheim, Eli Lilly,, Ironwood GlaxoSmithKline, Ironwood GlaxoSmithKline, Ironwood Pharmaceuticals, Johnson & Pharmaceuticals, Johnson & Pharmaceuticals, Johnson & Johnson, Reata, Relypsa, and Sanofi Johnson, Merck, Novartis, Opko, Johnson, Merck, Novartis, Opko, Ot k R t R l S d Ot k R t R l S d Uchenna Agbim, MD, MPH University of Tennessee Health University of Tennessee Health Gilead Science Center Science Center Cara L. Agerstrand, MD Columbia University Department of Columbia University Department of Medicine Medicine Vimla Aggarwal, MBBS CUIMC Mariam Aghajan, PhD Ionis Pharmaceuticals Ionis Pharmaceuticals Ionis Pharmaceuticals Arash Aghajani Nargesi, MD, MPH Mayo Clinic Mayo Clinic Central Society for Clinical and American Heart Association (AHA) Translational Research: CSCTR in Post-doctoral fellowship award the amount of $500 for an oral presentation of my research in the annual 2018 meeting Mohsen Agharazii, MD CHUQ-HDQ CHU de Québec-HDQ Helga Agostinho Fundação Faculdade Regional de Fundação Faculdade Regional de Medicina Medicina Shagun Agrawal UCSB UCSB Tarunveer S. Ahluwalia, PhD Steno Diabetes Center Copenhagen Steno Diabetes Center Copenhagen Kaashif A. Ahmad, MD MEDNAX National Medical Group Abbott Laboratories 10/22/2019 ASN Kidney Week 2019 Disclosures 2 Nothing to Full Name Organization Current Employer Consultancy Ownership Interest Research Funding Honoraria Patents and Inventions Scientific Advisor or Membership Speakers Bureau Other Interests/Relationships Disclose Sofia B. Ahmed, MD University of Calgary University of Calgary Advisory Board Member, Canadian Institutes of Health Research Institute of Gender and Health (volunteer position); (http://www.cihr- irsc.gc.ca/e/50746.html); Education Chair, Organization for the Study of Sex Differences (htt // d b /) Curie Ahn, MD, PhD Seoul National University Hospital Seoul National University Hospital Wooin Ahn, MD Columbia University Medical Center Christof Aigner, MD Medical University of Vienna Medical University of Vienna Sanofi Aventis ERA-EDTA member Medha Airy, MD, MBBS, MPH Baylor College of Medicine Baylor College of Medicine Amrendra Kumar Ajay, MS, PhD Brigham and Women's Hospital, Brigham and Women's Hospital Harvard Medical School Yasuhiro Akai, MD, PhD, FASN Nara Medical University Nara Medical University MSD K.K., Ono Pharmaceutical, Otsuka Pharmaceutical, Sumitomo Dainippon Pharma, Daiichi Sankyo, Eli Lilly Japan K.K., Torii Pharmaceutical, Teijin Pharma, Sanofi K.K., Kowa Pharmaceutical, Chugai Pharmaceutical, Novo Nordisk Pharma, Baxter, Kissei Pharmaceutical, Mitsubishi Tanabe Pharma, Boehringer Ingelheim Alireza Akbari, PhD London Health Sciences Centre Western University Ayub Akbari, MD, FASN University of Ottawa Ortho-Biotech,boehringer ingelheim, Ortho-Biotech, Merck, Sanofi-Aventis, GE, Merck, Sanofi_Aventis, Pfizer, Pfizer, Amgen. Amgen, BMS Oleh M. Akchurin, MD Weill Cornell College of Medicine Weill Cornell College of Medicine ASN and ASPN/IPNA member Radha Akella, PhD UT Southwestern Medical Center at UT Southwestern Medical Center at Dallas Dallas Kenichi Akiyama Tokyo Women's Medical University Tokyo Women's Medical University Kyowa Kirin Pharmaceutical Development, Inc. Elvis A. Akwo, MD, PhD Vanderbilt University Medical Center Vanderbilt University Medical Center Grace M. Alagadan, CNN Satellite Healthcare/Wellbound Satellite Healthcare/Wellbound Ziyad Al-Aly, MD, FASN VA Saint Louis Health Care System VA Saint Louis Health Care System VA (Department of Veteran Affairs).; Board of Directors, Veterans Institute for Public Health, Washington Research and Education Foundation University in Saint Louis of Saint Louis; Editorial boards: JASN, CJASN, Transplant International, Clinical Nephrology, European Medical Journal-Nephrology.; ASN Publications Committee Anam Alam Virginia Commonwealth University Virginia Commonwealth University Marco A. Alba, MD, PhD University of North Carolina at Chapel University of North Carolina at Chapel Hill Hill Valeria Gabriela Alberton hospital Fernandez Hospital Fernandez Barbara T. Alexander, PhD University of Mississippi Medical University of Mississippi Medical Editorial Board Membership:; Awards Committee member of the Center Center Hypertension Journal of the AHA; AHA Council on Hypertension American Journal of Physiology; Renal; Heart and Circulatory; Integrative, Regulatory and Comparative; Developmental
Load more

Recommended publications
  • Tetraphase Pharmaceuticals, Inc
    WBB Securities, LLC Steve Brozak, DMH [email protected] (908) 518-7610 Tetraphase Pharmaceuticals, Inc. (NasdaqGS: TTPH) Initiating Coverage Initiating Coverage with a Speculative Buy Rating February 22, 2018 and a 12-Month Price Target of $6.00 Tetraphase Prepares for Commercialization of a Needed Antibiotic Tetraphase Pharmaceuticals, Inc. (TTPH) is Current Price $2.20 a clinical stage pharmaceutical company, 12 Month Target Price $6.00 with eravacycline as its lead candidate. It is a novel tetracycline-derived antibiotic to 12-Month Trading Range $2.05-$9.93 treat resistant and multidrug-resistant Market Capitalization (Mil) $113.50 infections, including multidrug-resistant Shares Outstanding (Mil) 51.59 Gram-negative infections. Following Avg. Daily Volume 872,642 successful IGNITE1 and IGNITE4 Phase 3 L.T. Debt (Mil) 0.00 trials in complicated intra-abdominal infections (cIAI), a New Drug Application Dividend/Yield N/A (NDA) was filed with the FDA and a Book Value P/S $2.92 Marketing Authorisation Application (MAA) was submitted to the EMA for IV NASDAQ Composite 7,218.23 eravacycline. S&P 500 2,701.33 Historical Performance and Disclosures on Page 10 - 11 Two days ago, TTPH announced an exclusive Source: QUODD+ licensing agreement with Everest Medicines Limited, a C-bridge Capital-backed biopharmaceutical company based in China, to develop and commercialize eravacycline in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore (known as the Territories). Tetraphase will receive an initial upfront payment of $7.0 million and may receive clinical and regulatory milestones of up to $16.5 million as well as a maximum of $20.0 million via achieving annual sales milestones.
    [Show full text]
  • From the Academy
    FROM THE ACADEMY Joint American Academy of DermatologyeNational Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy Craig A. Elmets, MD (Co-Chair),a HenryW.Lim,MD,b Benjamin Stoff, MD, MA,c Cody Connor, MD,a Kelly M. Cordoro, MD,d Mark Lebwohl, MD,e AprilW.Armstrong,MD,MPH,f Dawn M. R. Davis, MD,g Boni E. Elewski, MD,a Joel M. Gelfand, MD, MSCE,h Kenneth B. Gordon, MD,i AliceB.Gottlieb,MD,PhD,j Daniel H. Kaplan, MD, PhD,k Arthur Kavanaugh, MD,l Matthew Kiselica, BA/BS,m Dario Kivelevitch, MD,n Neil J. Korman, MD, PhD,o Daniela Kroshinsky, MD, MPH,p Craig L. Leonardi, MD,q Jason Lichten, MD,m NehalN.Mehta,MD,MSCE,r Amy S. Paller, MD,s Sylvia L. Parra, MD,t Arun L. Pathy, MD,u Elizabeth A. Farley Prater, MD,v Reena N. Rupani, MD,e Michael Siegel, PhD,m BruceE.Strober,MD,PhD,w,x Emily B. Wong, MD,y Jashin J. Wu, MD,z Vidhya Hariharan, PhD,aa and Alan Menter, MD (Co-Chair)n Birmingham, Alabama; Detroit, Michigan; Atlanta, Georgia; San Francisco, Los Angeles, San Diego, and Irvine, California; New York, New York; Rochester, Minnesota; Philadelphia and Pittsburgh, Pennsylva- nia; Milwaukee, Wisconsin; Portland, Oregon; Dallas and San Antonio, Texas; Cleveland, Ohio; Boston, Massachusetts; St. Louis, Missouri; Bethesda, Maryland; Chicago and Rosemont, Illinois; Sumter, South Carolina; Centennial, Colorado; Oklahoma City, Oklahoma; Farmington, Connecticut; and Waterloo, Ontario, Canada Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 3.2% of the world’s population.
    [Show full text]
  • The Top 100 November, 2016 a List of Stocks Topping Our Custom 'Torpedo’ Screen
    The Top 100 November, 2016 A list of stocks topping our custom 'torpedo’ screen. Updated monthly. GPRO GoPro, Inc. Class A Consumer Discretionary TSLA Tesla Motors, Inc. Consumer Discretionary UA Under Armour, Inc. Class A Consumer Discretionary CRC California Resources Corp Energy CRZO Carrizo Oil & Gas, Inc. Energy CWEI Clayton Williams Energy, Inc. Energy FANG Diamondback Energy, Inc. Energy GST Gastar Exploration, Inc. Energy MPLX MPLX LP Energy RSPP RSP Permian, Inc. Energy SLCA U.S. Silica Holdings, Inc. Energy AAC AAC Holdings, Inc. Health Care ABEO Abeona Therapeutics, Inc. Health Care ACAD ACADIA Pharmaceuticals Inc. Health Care ADMP Adamis Pharmaceuticals Corporation Health Care ADMS Adamas Pharmaceuticals, Inc. Health Care ADXS Advaxis, Inc. Health Care AIMT Aimmune Therapeutics Inc Health Care AKBA Akebia Therapeutics, Inc. Health Care ALDR Alder Biopharmaceuticals, Inc. Health Care ARDM Aradigm Corporation Health Care ARDX Ardelyx, Inc. Health Care ARLZ Aralez Pharmaceuticals Inc. Health Care ATRA Atara Biotherapeutics Inc Health Care BCRX BioCryst Pharmaceuticals, Inc. Health Care BLUE bluebird bio, Inc. Health Care CARA Cara Therapeutics Inc Health Care CDNA CareDx, Inc. Health Care CEMP Cempra, Inc. Health Care CERS Cerus Corporation Health Care CFMS ConforMIS Inc Health Care CLVS Clovis Oncology, Inc. Health Care COLL Collegium Pharmaceutical, Inc. Health Care CORI Corium International, Inc. Health Care CRMD CorMedix Inc. Health Care CSU Capital Senior Living Corporation Health Care DERM Dermira Inc Health Care DVAX Dynavax Technologies Corporation Health Care DXCM DexCom, Inc. Health Care EPZM Epizyme, Inc. Health Care FOLD Amicus Therapeutics, Inc. Health Care HRTX Heron Therapeutics Inc Health Care ICPT Intercept Pharmaceuticals, Inc.
    [Show full text]
  • • La Gestion Efficace De L’Énergie • Le Réseautage Planétaire • Les Processus Géophysiques • L’Économie Globale, La Sécurité Et La Stabilité
    SupérieureS atiqueS athéM e M inaire D SéM The planet on which we live and the challenges that we face on this planet become increasingly complex as ecological, economic and social systems are large intertwined networks governed by dynamic processes and feedback loops. Mathematical models are indispensable in understanding and managing such systems since they provide insight into governing processes; they help predict future behavior; and they allow for risk-free evaluation of possible interventions. The goal of this thematic program is to tackle pressing and emerging challenges in population and ecosystem health, including understanding and controlling major transmissible diseases, optimizing and monitoring vaccination, predicting the impacts of climate change on invasive species, protecting biodiversity and managing ecosystems sustainably. This pan-Canadian program will bring together the international community of researchers who work on these topics in a series of workshops to foster exchange and stimulate cross-disciplinary research between all scientific areas involved, to discuss perspectives and directions for future advances in the field, including new models and methods and to foster tighter links between the research community, government agencies and policy makers. Three summer schools will introduce graduate students and postdoctoral fellows to the art of modeling living systems and to the latest tools and techniques to analyze these models. SCIENTIFIC COMMITTEE Jacques Bélair Mark Lewis (Montréal) Models and Methods in Ecology (Alberta) Frithjof Lutscher and Epidemiology Mathematical Modeling James Watmough (Ottawa) February 6-8, 2013 (UNB) of Indigenous Population Jianhong Wu CRM, Montréal (York) Organizers: Jacques Bélair (Montréal), Health Jianhong Wu (York) September 28-29, 2013 AISENSTADT CHAIRS BIRS Bryan Grenfell (Princeton), May 2013 Graphic Design: www.neograf.ca Simon A.
    [Show full text]
  • Clinical Characteristics and Risk Factors for Developed COVID-19 Patients Transferring to Designated Hospital from Jianghan Fang
    medRxiv preprint doi: https://doi.org/10.1101/2020.04.21.20074724; this version posted April 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Clinical Characteristics and Risk factors for developed COVID-19 patients transferring to designated hospital from Jianghan Fangcang shelter Hospital: a retrospective, observational study 1Yunfei Liao#, 2Yong Feng #, 3Bo Wang#, 1Hanyu Wang, 4Jinsha Huang, 5Yaxin Wu, 1Ziling Wu, 1Xiao Chen, 6Chao Yang, 7Xinqiao Fu and 1Hui Sun 1Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (Y Liao MD PhD, H Wang MD, Z Wu MD, X Chen MD, H Sun MD); 2Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (Y Feng MD PhD); 3Department of Rehabilitation, Wuhan No.1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (B Wang MD); 4Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (J Huang MD PhD); 5First Clinical College, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China (Y Wu BD) 6Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (C Yang MD PhD); 7Outpatient Department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China (X Fu PhD) # Contributed equally Correspondence to Hui Sun MD, Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China Email: [email protected] 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • NASDAQ Stock Market
    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
    [Show full text]
  • Fall 2016 Is Available in the Laboratory of Dr
    RNA Society Newsletter Aug 2016 From the Desk of the President, Sarah Woodson Greetings to all! I always enjoy attending the annual meetings of the RNA Society, but this year’s meeting in Kyoto was a standout in my opinion. This marked the second time that the RNA meeting has been held in Kyoto as a joint meeting with the RNA Society of Japan. (The first time was in 2011). Particular thanks go to the local organizers Mikiko Siomi and Tom Suzuki who took care of many logistical details, and to all of the organizers, Mikiko, Tom, Utz Fischer, Wendy Gilbert, David Lilley and Erik Sontheimer, for putting together a truly exciting and stimulating scientific program. Of course, the real excitement in the annual RNA meetings comes from all of you who give the talks and present the posters. I always enjoy meeting old friends and colleagues, but the many new participants in this year’s meeting particularly encouraged me. (Continued on p2) In this issue : Desk of the President, Sarah Woodson 1 Highlights of RNA 2016 : Kyoto Japan 4 Annual Society Award Winners 4 Jr Scientist activities 9 Mentor Mentee Lunch 10 New initiatives 12 Desk of our CEO, James McSwiggen 15 New Volunteer Opportunities 16 Chair, Meetings Committee, Benoit Chabot 17 Desk of the Membership Chair, Kristian Baker 18 Thank you Volunteers! 20 Meeting Reports: RNA Sponsored Meetings 22 Upcoming Meetings of Interest 27 Employment 31 1 Although the graceful city of Kyoto and its cultural months. First, in May 2016, the RNA journal treasures beckoned from just beyond the convention instituted a uniform price for manuscript publication hall, the meeting itself held more than enough (see p 12) that simplifies the calculation of author excitement to keep ones attention! Both the quality fees and facilitates the use of color figures to and the “polish” of the scientific presentations were convey scientific information.
    [Show full text]
  • Care of Pediatric Patients During COVID-19 Pandemic
    Care of Pediatric Patients during COVID-19 Pandemic Wuhan United “Living Through A Pandemic” Series 4 Co-organized with: Department of Pediatrics, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Forti & Consevage, P.C., Pennsylvania, USA Mead Johnson Nutrition, USA MEDICAL DISCLAIMER THIS PRESENTATION IS FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY AND MAY NOT BE CONSTRUED AS MEDICAL ADVICE. THE INFORMATION IS NOT INTENDED TO REPLACE MEDICAL ADVICE OFFERED BY PHYSICIANS. Contents 1. Opening remarks: Dr. Runming Jin 2. Diagnosis, Treatment and Prevention of COVID-19 in Children: Dr. Xiaoyan Wu 3. Management of Wards of Pediatric Hematological-Malignancy during COVID-19: Dr. Xiaoyan Wu 4. Protection for Medical Staff: Dr. Lei Li 5. Management of Children with other Non-COVID 19 related Health Care Needs: Dr. Lei Li Opening Remarks Runming Jin Clinical Professor, Department Chair Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Diagnosis, Treatment and Prevention of COVID-19 in Children Xiaoyan Wu MD, PhD, Associate Professor Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Information of Pediatric Patients in China • 2143 pediatric patients with COVID-19 were reported to the Chinese Center for Disease Control and Prevention from January 16 to February 8, 2020 • 731 (34.1%) laboratory-confirmed cases and 1412 (65.9%) suspected cases. • 1213 cases (56.6%) were boys. The age of disease onset ranged from 1.5m to 17y. • The median time from illness onset to diagnoses was 2 days (range: 0 to 42 days). • Of the 2143 pediatric patients, only one child died.
    [Show full text]
  • Olga G. Troyanskaya - Sciencewatch.Com
    Olga G. Troyanskaya - ScienceWatch.com Home About Scientific Press Room Contact Us ● ScienceWatch Home ● Interviews Featured Interviews Author Commentaries Institutional Interviews 2008 : September 2008 - Author Commentaries : Olga G. Troyanskaya Journal Interviews Podcasts AUTHOR COMMENTARIES - 2008 ● Analyses September 2008 Featured Analyses Olga G. Troyanskaya What's Hot In... Featured Scientist from Essential Science IndicatorsSM Special Topics Dr. Olga Troyanskaya has been named a Rising Star in the field of Computer ● Data & Rankings Science, according to an analysis published by ScienceWatch.com in May. Her citation record in this field in Essential Science Indicators from Thomson Sci-Bytes Reuters includes 31 papers cited a total of 1,533 times between January 1, 1998 and April 30, 2008. She also has Highly Cited Papers in the field of Fast Breaking Papers Clinical Medicine. Dr. Troyanskaya is an Assistant Professor in the New Hot Papers +enlarge Department of Computer Science and the Lewis-Sigler Institute for Integrative Emerging Research Fronts Genomics at Princeton University. Fast Moving Fronts Research Front Maps In the interview below, she talks with us about her highly cited work. Current Classics Top Topics Please tell us a little about your research and educational background. Rising Stars My background is interdisciplinary—I have a Ph.D. in Biomedical Informatics and undergraduate New Entrants degrees in both Computer Science and Biology. My research has always reflected this—I have been involved in bioinformatics research since undergraduate days, first working with Steven Salzberg, then at Country Profiles Johns Hopkins University and The Institute for Genomic Research, and then with Gad Landau and Alex Bolshoy at Haifa University in Israel.
    [Show full text]
  • Saipan Were Found Monday in Sand Project Is Resumed
    ,, .... ar1anas• M·ack, Conley found dead at Obyan Beach By Nick Legaspi from where Mack's light brown Chevy Blazer was parked. Staff reporter The person called the police. The bodies of Galen Mack and Remedio C. Conley were Manibusan said the clothed bodies, which were identi­ }~CJ:~" ...-:c· .. found Wednesday night at Obyan Beach, Public Safety fied through pictures given to the police by the victims' fa­ . ....~:-'·•{. -:-.~ ,~- '".. ' Director Edward Manibusan said Thursday. milies, had puncture wounds. However, he declined to Manibusan said in a press conference that a private specify if the wounds were stab or gunshot citizen found the bodies in the boonies about half a mile east See "GA YLEN MACK", page 19 Officers examine scene when truck was found. Tenorio signs '· budgets; CUC now· is funded By Nick Legaspi $892,000 for the operation of the Staff reporter House of Representatives, Governor Pedro P. Tenorio $988,000 for the operation of the signed a $9.2-million budget Senate and $200,000 for the op­ Tuesday for the operation of the eration of the Legislative Bureau. legislative and judicial branches The judicial branch will re­ and the Commonwealth Utilities ceive $481,700 for operations Corp. in fiscal year 1988. while t!te CUC will get $5.9 mil­ I J Public Law 5-44 breaks down lion. ~~oking over the b~nes are (from. left; Joseph Deleon Guerrero and Diego Camacho. See additional photo, page the constitutionally set legisla­ The first app;opriation law for tive budget of $2.8 million into fiscal year 1988 which began $720,000 for salaries of nine Oct.I allocates $70,000 from the Bones delivered to newspaper senators and 15 representatives, See"BUDGETS SIGNED", Page 7 project aids in island's history By Nick Legaspi facts or bones are found and to notify the Division of Manglona says Staff reporter Historic Preservation and to let the latter agency Pieces of bones of at least two prehistoric human recover the ancient remains before the construction inhabitants of Saipan were found Monday in sand project is resumed.
    [Show full text]
  • Annual Report 2020 03 Corporate Information
    Our Vision Dedicate to become a first-tier enterprise in the global mainstream pharmaceutical and healthcare market. Our Mission Better health for families worldwide. 02 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Contents 04 Corporate Information 07 Financial Highlights 08 Chairman’s Statement 12 Management Discussion and Analysis 67 Five-Year Statistics 68 Report of the Directors 91 Supervisory Committee Report 93 Corporate Governance Report 104 Environmental, Social and Governance Report 135 Biographical Details of Directors, Supervisors and Senior Management 144 Independent Auditor’s Report 149 Consolidated Statement of Profit or Loss 150 Consolidated Income Statement 151 Consolidated Statement of Financial Position 153 Consolidated Statement of Changes in Equity 155 Consolidated Statement of Cash Flows 157 Notes to Financial Statements 276 Definitions Annual Report 2020 03 Corporate Information Directors Authorized Representatives Executive Director Mr. Wu Yifang (吳以芳)11 Mr. Wu Yifang (吳以芳) Ms. Kam Mei Ha Wendy (甘美霞) (Chairman1 and Chief Executive Officer) Mr. Chen Qiyu (陳啟宇)12 Non-executive Directors Strategic Committee Mr. Chen Qiyu (陳啟宇)2 Mr. Chen Qiyu (陳啟宇) (Chairman) Mr. Yao Fang (姚方)3 Mr. Wu Yifang (吳以芳) Mr. Xu Xiaoliang (徐曉亮) Mr. Yao Fang (姚方) Mr. Gong Ping (龔平)4 Mr. Xu Xiaoliang (徐曉亮) Mr. Pan Donghui (潘東輝)4 Ms. Li Ling (李玲) Mr. Zhang Houlin (張厚林)5 Mr. Liang Jianfeng (梁劍峰)6 Audit Committee Mr. Wang Can (王燦)7 Ms. Mu Haining (沐海寧)9 Mr. Tang Guliang (湯谷良) (Chairman) Mr. Jiang Xian (江憲) Independent Non-executive Directors Mr. Gong Ping (龔平)4 Mr. Jiang Xian (江憲) Mr. Wang Can (王燦)7 Dr. Wong Tin Yau Kelvin (黃天祐) Ms.
    [Show full text]
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]